Affimed N.V. (NASDAQ:AFMD) dropped ~21% premarket Wednesday after the German biotech announced a 1-for-10 reverse stock split of its common stock to regain compliance with Nasdaq listing rules.
Accordingly, every ten shares of AFMD’s outstanding common stock with a par value of €0.01 per share will convert to one such unit.
The reverse stock split takes effect on March 8, 2024, after the market close. AFMD stock is expected to begin trading on a split-adjusted basis on March 11, 2024, under the same ticker symbol.
The decision comes after the company’s shareholders approved the reverse stock split during AFMD’s annual general meeting in June 2023.
It is intended to help Affimed (AFMD) regain compliance with the minimum $1.00 per share requirement needed for continued listing on Nasdaq.